investigator_user
investigator
user
funding
collaborators
pending
menu
bell
message
arrow_up
arrow_down
filter
layers
globe
marker
add
arrow
close
download
edit
facebook
info
linkedin
minus
plus
save
share
search
sort
twitter
remove
user-plus
user-minus
Sign Up for Updates
Map
Countries
Cancer types
All cancers but non-melanoma skin cancer
Bladder
Brain, nervous system
Breast
Cervix uteri
Colorectum
Corpus uteri
Gallbladder
Hodgkin lymphoma
Kaposi sarcoma
Kidney, renal pelvis and ureter
Larynx
Leukaemia
Lip, oral cavity
Liver and intrahepatic bile ducts
Melanoma of skin
Multiple myeloma and immunoproliferative diseases
Nasopharynx
Non-Hodgkin lymphoma
Non-Melanoma skin cancer
Oesophagus
Other pharynx
Ovary
Pancreas
Prostate
Sarcoma
Stomach
Testis
Thymus
Thyroid
Trachea, bronchus and lung
Specialities
Hematology and hematologic malignancies
Palliative Care
Pathology
Pediatric oncology or childhood cancer
Radiation Oncology
Surgery / Surgical oncology
Blog
About
Login
Project leads
Collaborators
Decision Models to Compare Treatments in Older Patients with AML
Martine Extermann
3 Collaborator(s)
Funding source
National Cancer Institute (NIH)
Follow
+ Project
+ Post
+ Event
Info
People
Posts
Norbert Vey
Institute Paoli-Calmettes
Marseille, France
Ulrich Wedding
Friedrich Schiller University Jena
Jena, Germany
Robert Lowenberg
Erasmus University Medical Center
Rotterdam, Netherlands
Martine Extermann
Moffitt Cancer Center
Tampa, United States
University of South Florida
Tampa, United States
Related projects
Thomas J O'Hare
Mechanisms of Resistance to Ponatinib Therapy in Chronic Myeloid Leukemia
Leukaemia
Hematology and hematologic malignancies
Ronald Hoffman
A New Murine Model for MPN: Pathology and Therapy of NF-E2 Overexpression
Leukaemia
Hematology and hematologic malignancies
Targeting BCL6 in Tyrosine Kinase-Driven Leukemia
Leukaemia
Hematology and hematologic malignancies
Karin L Gaensler
Efficacy and Safety of Novel CD80 IL15 IL15Ra Expressing Autologous AML Vaccines
Leukaemia
Hematology and hematologic malignancies
Catherine Ju-Ying Wu
(PQD1) Impact of Cytotoxic and Targeted Therapy on Clonal Evolution of CLL
Leukaemia
Hematology and hematologic malignancies
Richard Aplenc
Toxicity Monitoring on Phase III Trials with Administrative Data
Leukaemia
Hematology and hematologic malignancies
William E Evans
Pharmacogenomics of Childhood Leukemia (ALL)
Leukaemia
Hematology and hematologic malignancies
Reuben Kapur
Role of p21 Activated Kinase in Leukemogenesis
Leukaemia
Hematology and hematologic malignancies
Ronald Hoffman
Myeloproliferative Disorders (MPD) Research Consortium
Leukaemia
Hematology and hematologic malignancies
